LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 816

Search options

  1. Article ; Online: Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia.

    Nakano, Masahito / Kawaguchi, Machiko / Kawaguchi, Takumi

    Journal of hepatology

    2024  Volume 80, Issue 4, Page(s) e155–e157

    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease/complications ; Liver Cirrhosis ; Asia/epidemiology
    Language English
    Publishing date 2024-01-13
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2023.12.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia.

    Suzuki, Hiroyuki / Tsutsumi, Tsubasa / Kawaguchi, Machiko / Amano, Keisuke / Kawaguchi, Takumi

    Clinical and molecular hepatology

    2024  

    Language English
    Publishing date 2024-03-06
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2672560-5
    ISSN 2287-285X ; 2287-2728
    ISSN (online) 2287-285X
    ISSN 2287-2728
    DOI 10.3350/cmh.2024.0157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: [Liver rehabilitation:exercise therapy for patients with liver disease].

    Kawaguchi, Takumi / Matsuse, Hiroo

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

    2023  Volume 120, Issue 9, Page(s) 726–737

    MeSH term(s) Humans ; Liver Diseases/therapy ; Digestive System Diseases ; Exercise Therapy
    Language Japanese
    Publishing date 2023-08-25
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 708695-7
    ISSN 1349-7693 ; 0446-6586
    ISSN (online) 1349-7693
    ISSN 0446-6586
    DOI 10.11405/nisshoshi.120.726
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease.

    Nakano, Masahito / Kawaguchi, Machiko / Kawaguchi, Takumi / Yoshiji, Hitoshi

    Hepatology research : the official journal of the Japan Society of Hepatology

    2024  

    Abstract: Aim: In patients with steatotic liver disease (SLD), significant hepatic fibrosis is a prognostic factor with various etiologies, including inflammation and metabolic dysfunction. This study aimed to investigate independent factors and profiles ... ...

    Abstract Aim: In patients with steatotic liver disease (SLD), significant hepatic fibrosis is a prognostic factor with various etiologies, including inflammation and metabolic dysfunction. This study aimed to investigate independent factors and profiles associated with significant hepatic fibrosis, including alanine aminotransferase (ALT) levels >30 U/L and metabolic dysfunction-associated SLD (MASLD), in health check-up examinees.
    Methods: This single-center, retrospective, observational cohort study enrolled 1378 consecutive health checkup examinees from April 2018 to September 2022. Shear wave elastography (SWE) was performed during a routine ultrasound examination, and patients with liver stiffness ≥6.60 kPa were defined as having significant hepatic fibrosis. Patients were classified into nonsignificant hepatic fibrosis (n = 1220) or a significant hepatic fibrosis (n = 158) group according to this definition.
    Results: In multivariate analysis, the independent factor for significant hepatic fibrosis was aging (≥65 years; OR 9.637, 95% CI 6.704-13.852, p < 0.0001). According to decision tree analysis, the initial classifier was aging (≥65 years). After aging, an ALT level >30 U/L was the second relevant factor for significant hepatic fibrosis, regardless of age. An undirected graphical model showed that an ALT level of >30 U/L was directly associated with significant hepatic fibrosis. In patients aged ≥65 years with an ALT level >30 U/L, significant hepatic fibrosis was observed in 52% of the patients. Meanwhile, in patients aged ≥65 years with an ALT level ≤30 U/L, MASLD was the third classifier, with significant hepatic fibrosis observed in 38% of patients.
    Conclusions: ALT levels >30 U/L and MASLD may be involved in the pathogenesis of significant hepatic fibrosis in patients aged ≥65 years.
    Language English
    Publishing date 2024-01-31
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1387041-5
    ISSN 1386-6346 ; 0928-4346
    ISSN 1386-6346 ; 0928-4346
    DOI 10.1111/hepr.14020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Changing from NAFLD to MASLD: The implications for health-related quality of life data.

    Hashida, Ryuki / Nakano, Dan / Kawaguchi, Machiko / Younossi, Zobair M / Kawaguchi, Takumi

    Journal of hepatology

    2024  

    Language English
    Publishing date 2024-02-23
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2024.02.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.

    Tsutsumi, Tsubasa / Nakano, Dan / Kawaguchi, Machiko / Takahashi, Hirokazu / Kawaguchi, Takumi

    Clinical and molecular hepatology

    2024  Volume 30, Issue 2, Page(s) 266–268

    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/diagnosis ; Non-alcoholic Fatty Liver Disease/metabolism ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/diagnosis
    Language English
    Publishing date 2024-01-30
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2672560-5
    ISSN 2287-285X ; 2287-2728
    ISSN (online) 2287-285X
    ISSN 2287-2728
    DOI 10.3350/cmh.2024.0028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Endoscopic hand-suturing training model.

    Morita, Taku / Ohata, Ken / Araki, Toshihiro / Koda, Makoto / Fukumori, Kazuta / Minato, Yohei / Kawaguchi, Takumi

    Endoscopy

    2024  Volume 56, Issue S 01, Page(s) E299–E300

    MeSH term(s) Humans ; Stomach/surgery ; Sutures ; Suture Techniques
    Language English
    Publishing date 2024-04-03
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 80120-3
    ISSN 1438-8812 ; 0013-726X
    ISSN (online) 1438-8812
    ISSN 0013-726X
    DOI 10.1055/a-2282-9977
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development.

    George, Jacob / Kawaguchi, Takumi

    Hepatology international

    2022  Volume 16, Issue 4, Page(s) 733–736

    MeSH term(s) Humans ; Liver/metabolism ; Liver Neoplasms/etiology ; Liver Neoplasms/metabolism ; Metabolic Syndrome ; Obesity/metabolism
    Language English
    Publishing date 2022-06-13
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2270316-0
    ISSN 1936-0541 ; 1936-0533
    ISSN (online) 1936-0541
    ISSN 1936-0533
    DOI 10.1007/s12072-022-10352-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.

    Suzuki, Hiroyuki / Shimose, Shigeo / Iwamoto, Hideki / Niizeki, Takashi / Kawaguchi, Takumi

    Clinical and molecular hepatology

    2024  Volume 30, Issue 2, Page(s) 263–265

    MeSH term(s) Humans ; Bevacizumab/therapeutic use ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/diagnosis ; Non-alcoholic Fatty Liver Disease/drug therapy ; Carcinoma, Hepatocellular/complications ; Carcinoma, Hepatocellular/drug therapy ; Liver Neoplasms/complications ; Liver Neoplasms/drug therapy ; Prognosis ; Antibodies, Monoclonal, Humanized
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-01-18
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2672560-5
    ISSN 2287-285X ; 2287-2728
    ISSN (online) 2287-285X
    ISSN 2287-2728
    DOI 10.3350/cmh.2023.0557
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Recent Progress of Nutritional Management for Liver Cirrhosis.

    Kawaguchi, Takumi / Kato, Akinobu

    Journal of nutritional science and vitaminology

    2022  Volume 68, Issue Supplement, Page(s) S73–S75

    Abstract: Evidence-based Clinical Practice Guidelines for Liver Cirrhosis were updated in 2021 by The Japanese Society of Gastroenterology/Japan Society of Hepatology. In the guidelines, the flowchart for nutritional therapy was revised based on accumulated ... ...

    Abstract Evidence-based Clinical Practice Guidelines for Liver Cirrhosis were updated in 2021 by The Japanese Society of Gastroenterology/Japan Society of Hepatology. In the guidelines, the flowchart for nutritional therapy was revised based on accumulated evidence. In particular, sarcopenia is incorporated as an assessment for nutritional status. In addition, late evening snack is repositioned as a 1st-line nutritional therapy. Furthermore, recent study demonstrated unforeseen pharmacological actions of branched-chain amino acids including improving sarcopenia and prognosis. In this mini-review, we summarize the updated points for nutritional therapy for patients with liver cirrhosis.
    MeSH term(s) Humans ; Sarcopenia/therapy ; Liver Cirrhosis/complications ; Liver Cirrhosis/therapy ; Amino Acids, Branched-Chain ; Nutritional Status ; Snacks
    Chemical Substances Amino Acids, Branched-Chain
    Language English
    Publishing date 2022-09-23
    Publishing country Japan
    Document type Review ; Journal Article
    ZDB-ID 191366-9
    ISSN 1881-7742 ; 0301-4800
    ISSN (online) 1881-7742
    ISSN 0301-4800
    DOI 10.3177/jnsv.68.S73
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top